RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $409
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $387 to $409.
RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $387 to $409.